Fundamental Analysis of VAXCYTE INC(NASDAQ:PCVX) stock

Fundamental Rating

Taking everything into account, PCVX scores 3 out of 10 in our fundamental rating. PCVX was compared to 586 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PCVX as it has an excellent financial health rating, but there are worries on the profitability. PCVX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

PCVX had negative earnings in the past year.

In the past year PCVX has reported a negative cash flow from operations.

In the past 5 years PCVX always reported negative net income.

PCVX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PCVX's Return On Assets of -20.89% is fine compared to the rest of the industry. PCVX outperforms 79.49% of its industry peers.

PCVX has a Return On Equity of -22.02%. This is amongst the best in the industry. PCVX outperforms 84.44% of its industry peers.

		Industry Rank	Sector Rank
ROA	-20.89%
ROE	-22.02%
ROIC	N/A

ROA(3y)-27.21%

ROA(5y)-36.17%

ROE(3y)-30.37%

ROE(5y)-42.03%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PCVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for PCVX has been increased compared to 1 year ago.

The number of shares outstanding for PCVX has been increased compared to 5 years ago.

PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PCVX has an Altman-Z score of 44.79. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.

PCVX's Altman-Z score of 44.79 is amongst the best of the industry. PCVX outperforms 96.58% of its industry peers.

PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	44.79

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 17.42 indicates that PCVX has no problem at all paying its short term obligations.

PCVX's Current ratio of 17.42 is amongst the best of the industry. PCVX outperforms 90.60% of its industry peers.

A Quick Ratio of 17.42 indicates that PCVX has no problem at all paying its short term obligations.

PCVX's Quick ratio of 17.42 is amongst the best of the industry. PCVX outperforms 90.60% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	17.42
Quick Ratio	17.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for PCVX have decreased strongly by -24.06% in the last year.

EPS 1Y (TTM)-24.06%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-21.43%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 4.32% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-6.42%

EPS Next 2Y-5.21%

EPS Next 3Y-4.05%

EPS Next 5Y4.32%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCVX. In the last year negative earnings were reported.

Also next year PCVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -4.05% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.21%

EPS Next 3Y-4.05%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PCVX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VAXCYTE INC

NASDAQ:PCVX (5/17/2024, 7:19:06 PM)

After market: 74.57 0 (0%)

74.57

-0.88 (-1.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.11B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.89%
ROE	-22.02%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	17.42
Quick Ratio	17.42
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-24.06%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-6.42%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VAXCYTE INC (PCVX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens